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Abstract
Background: The use of TNF inhibitors has been a major progress in the treatment of chronic inflammation. However, not
all patients respond. In addition, response will be often lost when treatment is stopped. These clinical aspects indicate that
other cytokines might be involved and we focus here on the role of IL-17. In addition, the chronic nature of joint
inflammation may contribute to reduced response and enhanced chronicity. Therefore we studied the capacity of IL-17 to
regulate synoviolin, an E3 ubiquitin ligase implicated in synovial hyperplasia in human rheumatoid arthritis (RA) FLS and in
chronic reactivated streptococcal cell wall (SCW)-induced arthritis.
Methodology/Principal Findings: Chronic reactivated SCW-induced arthritis was examined in IL-17R deficient and wild-type
mice. Synoviolin expression was analysed by real-time RT-PCR, Western Blot or immunostaining in RA FLS and tissue, and
p53 assessed by Western Blot. Apoptosis was detected by annexin V/propidium iodide staining, SS DNA apoptosis ELISA kit
or TUNEL staining and proliferation by PCNA staining. IL-17 receptor A (IL-17RA), IL-17 receptor C (IL-17-RC) or synoviolin
inhibition were achieved by small interfering RNA (siRNA) or neutralizing antibodies. IL-17 induced sustained synoviolin
expression in RA FLS. Sodium nitroprusside (SNP)-induced RA FLS apoptosis was associated with reduced synoviolin
expression and was rescued by IL-17 treatment with a corresponding increase in synoviolin expression. IL-17RC or IL-17RA
RNA interference increased SNP-induced apoptosis, and decreased IL-17-induced synoviolin. IL-17 rescued RA FLS from
apoptosis induced by synoviolin knockdown. IL-17 and TNF had additive effects on synoviolin expression and protection
against apoptosis induced by synoviolin knowndown. In IL-17R deficient mice, a decrease in arthritis severity was
characterized by increased synovial apoptosis, reduced proliferation and a marked reduction in synoviolin expression. A
distinct absence of synoviolin expressing germinal centres in IL-17R deficient mice contrasted with synoviolin positive B cells
and Th17 cells in synovial germinal centre-like structures.
Conclusion/Significance: IL-17 induction of synoviolin may contribute at least in part to RA chronicity by prolonging the
survival of RA FLS and immune cells in germinal centre reactions. These results extend the role of IL-17 to synovial
hyperplasia.
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Introduction
Anti-TNF therapies have an established role in rheumatoid
arthritis (RA) treatment however in the clinic RA remains a
chronic disease with up to 40% nonresponders and subsequent
flares when TNF inhibitors are ceased. RA is characterised by
chronic synovial inflammation and hyperplasia. Synovial hyper-
plasia is a consequence of an imbalance between proliferation and
apoptosis of resident fibroblast-like synoviocytes (FLS). Resistance
of cells to apoptosis is partly due to the upregulation of molecules
counteracting the apoptosis cascade. There is substantial evidence
that synovial hypertrophy contributes to the chronicity of RA with
ultimately destructive consequences. Joint synovectomy by surgi-
cal, chemical or radiation measures, removes the pathologic
synovial tissue burden leading to cessation of arthritis and more
prolonged remission [1]. Similarly to cancer cells, RA FLS
demonstrate dysregulated proliferation and apoptosis, anchorage
independent growth, intrinsically express proto-oncogenes and
functional mutations in tumour suppressor genes such as p53 and
are capable of spontaneously invading human cartilage [2].
Up to 40% of RA patients are nonresponders to current anti-
TNF biologics suggesting that other molecules implicated in
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disease chronicity [3]. Recently, synoviolin a novel E3 ubiquitin
ligase present in the endoplasmic reticulum, was identified in RA
FLS and synovial lining tissue, and may be implicated in
dysregulated proliferation and apoptosis in RA [4]. The
overexpression of synoviolin leads to destructive arthritis in mice
[4]. In murine arthritis, synoviolin heterozygous knockout mice
are protected against arthritis development associated with
reduced synovial hypercellularity. In addition, synoviolin is
increased during the course of murine collagen induced arthritis
(CIA) [5]. In contrast to murine studies, the role of synoviolin in
human RA is less well understood. In vitro, synoviolin has been
reported to protect against both ER-stress-induced apoptosis in
RA FLS [4] and p53-mediated apoptosis in 293 cells [6]. In RA,
the proinflammatory cytokines IL-1 and TNF derived predomi-
nantly from synovial macrophages lead to sustained synoviolin
expression [3,5,7]. In vivo, synoviolin has been reported to be
elevated in a subset of circulating immune cell subsets which may
be associated with anti-TNF nonresponse [3].
IL-17 is a pleiotropic proinflammatory cytokine produced from
Th17 cells [8]. IL-17A is the prototypic member belonging to a
family of 6 ranging from IL-17A to IL-17F [9]. IL-17A mediates
its biological effects through binding to a receptor complex
consisting of IL-17RA and IL-17RC subunits which are expressed
in RA FLS [10]. The IL-17 receptor complex interacts with a
STIR (SEFIR, similar expression to fibroblast growth factor genes)
subdomain leading to activation of act1, TRAF6, nuclear factor
kappa B (NFkB), activator protein 1 (AP-1) and mitogen protein
kinases (MAPK) [10,11,12,13,14]. IL-17 has a critical role in RA
joint inflammation and destruction [15]. IL-17 has been described
to be implicated in synovial hypercellularity in murine arthritis
models [16]. In addition, IL-17RC has been reported to regulate
apoptosis [17]. The role of T-cell derived cytokines such as IL-17
in regulation of dysregulated apoptosis and proliferation in RA
FLS is not known. In this study, we demonstrate that IL-17R-
mediated induction of synoviolin contributes to chronic synovial
hyperplasia and inflammation by prolonging the survival of RA
FLS and germinal centre reactions.
Results
Synoviolin induction by IL-17 in RA FLS
We investigated the expression of synoviolin in cultured RA
FLS treated with IL-17A or IL-17F compared to IL-1, TNF and
LPS by real time RT-PCR and Western blot. Synoviolin was
constitutively expressed in RA FLS, and induced by IL-17A, IL-
17F, IL-1 or TNF at 24 h (Figure 1A, upper panel). The induction
of synoviolin expression by IL-17A at 12 h was weaker than
induction by IL-1b or LPS but stronger than IL-17F or TNF-a.
IL-17-induced synoviolin expression was confirmed at the protein
level. IL-17A was a more potent inducer of synoviolin compared
to IL-17F (Figure 1A, lower panel).
Given that IL-17A induced more robust synoviolin induction
than IL-17F, subsequent experiments were carried out with IL-17A
alone and hereby referred to as IL-17. We next determined the dose
range of synoviolin induction by IL-17. A dose dependent increase
insynoviolin mRNA byIL-17Awas observed (Figure1B,leftpanel).
The timecourse of IL-17 50 ng/ml induction of synoviolin was
examined over 24 hours. IL-17A induced significant synoviolin
mRNA expression at 6 h which increased and remained elevated
over 24 h (Figure 1B, right panel). IL-17A increased synoviolin
mRNA 4.9 fold at 24 h (P,0.05). In comparison with OA FLS or
OA dermal fibroblasts, IL-17-induced synoviolin expression was
more marked in RA FLS (Figure 1C).
ERK and JNK activation is required for IL-17 induced
expression of synoviolin
ERK MAPK and ETS1 transcription factor activation have
been described to modulate synoviolin expression in murine
cells[5]. To investigate the involvement of MAPK activation in IL-
17 induced synoviolin expression, RA FLS were preincubated with
MAPK inhibitors for 1 hour [18,19] and then treated with IL-17
50 ng/ml over 12 h. Inhibition of ERK (PD98059) or JNK
(SP600125) was associated with a marked reduction in synoviolin
mNA expression (Figure 1D). Although there was a trend, we did
not observe a statistically significant reduction in IL-17 induced
synoviolin expression in the presence of the p38 pathway inhibitor
(SB203580).
IL-17 protects RA FLS from SNP-induced apoptosis
To determine the functional significance of IL-17-induced
synoviolin expression in RA FLS, we examined the effects of IL-17
treatment on SNP-induced apoptosis. SNP induces apoptosis by
NO donation and leads to cell death by both ER-stress and p53-
mediated apoptosis [20,21,22]. RA FLS demonstrated low rates of
spontaneous apoptosis. SNP (0.1–1 mM) induced a significant
increase in apoptosis up to 70–80% of annexin V positive cells by
FACs analysis (data not shown) or by SS DNA fragmentation,
associated with decreased synoviolin expression at 6 and 24 h
(Figure 2A, B, P,0.05). Treatment of RA FLS by IL-17 over 24 h
significantly impaired SNP-induced apoptosis (Figure 2C). This
effect of IL-17 was confirmed by a reduction in SNP-induced
annexin V positive cells (Figure 2D, P,0.05).
Effect of IL-17RA or IL-17RC RNA interference on RA FLS
apoptosis
To confirm a protective role for IL-17R signaling in SNP-
induced apoptosis we next examined the effect of IL-17RA or IL-
17RC RNA interference in RA FLS. IL-17RA siRNA lead to a
72% inhibition of IL-17RA mRNA and protein expression,
whereas IL-17RC siRNA inhibited IL-17RC mRNA and protein
expression by 70% (Figure 3A, B). To determine the specificity of
RNA interference we examined the effects of IL-17RA or IL-
17RC interference on IL-17RA or IL-17RC expression. IL-17RA
RNA interference had either no effect or slightly increased IL-
17RC mRNA expression (Figure 3B). IL-17RC RNA interference
had no effect on IL-17RA mRNA expression (Figure 3B). In the
presence of IL-17, IL-17RA or IL-17RC RNA interference
significantly enhanced SNP 0.1 mM induced apoptosis in RA
FLS, with a 3 or 2.7 fold increase in apoptosis respectively
compared to sicontrol (Figure 3C, P,0.05), confirming a
protective effect of IL-17 on RA FLS apoptosis.
Effect of IL-17RA or IL-17RC RNA interference on
synoviolin expression
We next determined the effects of IL-17RA or IL-17RC RNA
interference on synoviolin expression. Both IL-17RA or IL-17RC
siRNA lead to near complete abrogation of IL-17-induced
synoviolin expression in RA FLS (Figure 3D). As expected IL-
17RA or IL-17RC RNA interference antagonism also reduced IL-
17-mediated p65 induction, whereas IL-17RA RNA interference
more potently suppressed IL-17-induced c-fos expression com-
pared to IL-17RC (data not shown). We confirmed IL-17R-
mediated modulation of synoviolin by the use of neutralising Abs
against IL-17RA or IL-17RC [23]. Anti-IL-17RA or anti-IL-
17RC Abs significantly antagonised IL-17-induced synoviolin
expression (Figure 3E, P,0.05).
IL-17 and Synoviocyte Survival
PLoS ONE | www.plosone.org 2 October 2010 | Volume 5 | Issue 10 | e13416Figure 1. Effect of IL-17 on synoviolin expression in RA FLS. RA FLS were stimulated with IL-17A or IL-17F (50 ng/ml), IL-1 10 ng/ml, TNF
10 ng/ml or LPS 100 ng/ml for 24 h and synoviolin mRNA expression measured by real-time RT-PCR (A, upper panel). The results based on a ratio of
synoviolin/b-actin mRNA amplification are presented as the fold induction in synoviolin mRNA expression relative to control samples, n=3, mean 6
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apoptosis
To determine if synoviolin may inhibit SNP-induced apoptosis
in RA FLS, we determined effects of synoviolin RNA interference
in RA FLS. We confirmed 80% knockdown of synoviolin mRNA
and protein by RNA interference in RA FLS (Figure 4A). Duplex
2 (S-02) was the most efficient and was chosen for subsequent
experiments. Synoviolin RNA interference increased SNP-induced
apoptosis by 4 fold in RA FLS (Figure 4B, P,0.05) demonstrating
the specificity of its contribution. To confirm that the anti-
apoptotic effects of IL-17 were mediated by synoviolin, we
demonstrated that the protective effects of IL-17 were completely
abrogated in the presence of synoviolin knockdown at the lowest
dose of SNP (Figure 4C, P,0.05). However, at higher concentra-
tions of SNP the anti-apoptotic effects of IL-17 could be reversed.
Effect of IL-17 and TNF on synoviolin expression and
apoptosis in RA FLS
IL-17 and TNF have synergistic or additive effects on many of
the biological activities of IL-17 [24]. As noted previously TNF
had a weaker effect on induction of synoviolin than IL-17A. IL-17
100 ng/ml in combination with TNF (1 or 10 ng/ml) had additive
effects on synoviolin induction in comparison with TNF alone
(P,0.05), but only trended to significance compared to IL-17
alone (Figure 5A).
Similarly, at the higher concentrations of SNP 0.5 mM (or 1 mM
data not shown) only the combination of IL-17 and TNF was
capable of completely abrogating RA FLS apoptosis in the
presence of synoviolin knockdown compared to either cytokine
alone (Figure 5B). At the lowest concentration of SNP 0.1 mM, IL-
17 but not TNF was capable of completely protecting RA FLS
from apoptosis induced by synoviolin knockdown. Some variabil-
ity in the potency of cytokine-induced synoviolin induction and
apoptosis was noted between different cell lines.
Reduced synoviolin expression in IL-17R deficient mice
during chronic SCW-induced arthritis.
To confirm the requirement of IL-17R-dependent signaling in
IL-17-induced synoviolin expression we examined the effects of
IL-17R deficiency on synoviolin expression. We first assessed
synoviolin expression histologically in injected knee joints of WT
mice during chronic SCW-induced arthritis. The synoviolin
positive cells in murine synovium were observed either diffusely
or in some sections almost entirely limited to follicle-like structures.
Serial sections of follicle-like structures, demonstrated that
synoviolin positive cells colocalised with IL-17 and CD19 positive
staining suggesting that synoviolin was expressed by both Th17
cells and CD19+ B cells (Figure 6A-E, isotype control 6F).
Synoviolin expression was also observed in RA FLS invading
cartilage at the pannus-cartilage junction in WT mice (Figure 6G).
As previously described [25], compared to WT mice, IL-17R
2/2
mice had reduced synovial hypercellularity leading to significantly
decreased macroscopic arthritis severity scores (Figure 7A, mean 6
SEM score 1.560.17 in WT versus 0.3160.10 in IL-17R
2/2 mice;
P,0.05).Similarly,incomparison toWTanimals,IL-17R
2/2 mice
histologically displayed markedly reduced inflammatory infiltrate
scores (mean 6 SEM score 2.560.43 in WT versus 0.8760.27 in
IL-17R
2/2 mice ; P,0.05). Synoviolin expression was reduced in
the synovial knee sections of IL-17R
2/2 compared to WT mice
(Figure 7B). In IL-17R
2/2 mice, synoviolin expression was either
weak or limited throughout the inflammatory infiltrate.
We next examined synovial apoptosis by TUNEL staining of
synovial knee joints from mice with chronic SCW-induced
arthritis. TUNEL staining was significantly increased in synovial
knee joints from IL-17R
2/2 mice than from WT mice (mean 6
SEM TUNEL-positive cells per high-power field 203621 versus
63618; P,0.05, Figure 7C).
In situ proliferation was detected by PCNA staining. In WT mice
with chronic SCW-induced arthritis, the number of proliferating
cells detected was 219652 PCNA-positive cells 6 SEM per high-
power field which was further reduced in IL-17R
2/2 mice
compared to WT mice (110615, Figure 7D).
Discussion
The chronicity of RA disease is not well understood.
Persistence of biological abnormalities in RA FLS or synovial
tissue despite disease-modifying treatment is supported by a
substantial proportion of nonresponders and the transient effects
of current gold standard treatment such as anti-TNF biologics.
New treatment regimens will need to go beyond the simple
c o n t r o lo fi n f l a m m a t i o ni fm o r e prolonged remissions are to be
achieved. Synoviolin is an E3 ubiquitin ligase implicated in
murine arthritis pathogenesis. Overexpression of synoviolin leads
to spontaneous destructive arthritis, and synoviolin
2/+ mice are
resistant to CIA [4]. The protective role of synoviolin in ER
stress-induced apoptosis and cell survival has been demonstrated
in RA FLS and other cell types [26,27,28,29]. In RA FLS, we and
others have demonstrated that synoviolin plays an important role
in RA FLS growth [4]. Synoviolin knockdown augments ER-
stress induced apoptosis and diminishes intrinsic and cytokine-
induced FLS proliferation. We recently observed expression of
synoviolin in T cells, macrophages and RA FLS, which is
increased by the predominantly macrophage-derived cytokines
I L - 1a n dT N Fk n o w nt or e g u l a t eR AF L Sc e l lg r o w t ha n d
survival [3]. In contrast, IL-17 derived from Th17 cells has not
been reported to modulate RA FLS cell growth. Indeed, reports
in the literature suggest that IL-17 regulates cell growth in only
certain cell types such as lymphocytes and data in cancer is
controversial. In this study, IL-17 exerts an anti-apoptotic effect,
mediated by IL-17RA and IL-17RC, associated with increased
synoviolin expression. These data s u g g e s tt h a tI L - 1 7c o n t r i b u t e s
to RA chronicity through both synovial inflammation and
hyperplasia.
An anti-apoptotic role for IL-17 is supported by data in IL-17R
knockout mice associated with markedly reduced synovial
hypercellularity [30]. Other proflammatory cytokines such as
TNF [31] and MIF [32] have been reported to contribute to
synovial hyperplasia and the increased survival of RA FLS. IL-17
rescued RA FLS from SNP-induced apoptosis and IL-17RA or
RC siRNA augmented SNP-induced apoptosis. An important role
SEM. * P,0.05 compared to no treatment control. RA FLS were treated with IL-17A or IL-17F (50 ng/ml) for 24 h and synoviolin expression measured
by Western Blotting (A, lower panel). The membrane was stripped and reprobed for b-actin and the result is representative of n=3. RA FLS were
treated with IL-17 5-200 ng/ml for 24 h (B, left panel) or IL-17 50 ng/ml over 24 h (B, right panel) and synoviolin expression measured by real-time
RT-PCR, n=3, mean 6 SEM, * P,0.05. Synoviolin mRNA expression in RA FLS, OA FLS and OA dermal fibroblasts that were untreated (–) or were
treated with 50 ng/ml or 10 ng/ml of IL-1 for 24 h (C). * P,0.05 versus untreated FLS. RA FLS were preincubated with PD98059 (50mM), SB203580
(5mM) or SP600125 (50mM) for 1 hour, then treated with IL-17 50 ng/ml for 1 hour. Synoviolin expression was measured by real-time PCR, mean 6
SEM, n=3 (D). * p,0.05 compared to IL-17 treatment.
doi:10.1371/journal.pone.0013416.g001
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PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13416Figure 2. Effect of IL-17 on RA FLS apoptosis. RA FLS were treated with SNP 0.01-1 mM for 24 h and apoptosis measured by SS DNA apoptosis
kit (A). The results are presented as the fold induction in apoptosis relative to control samples, n=3, mean 6 SEM of duplicate experiments from 3
different RA donors. * P,0.05 compared to no treatment control. RA FLS were treated with SNP 0.01–1 mM for 24 h (B, left panel) or 0.1 mM over
24 h (B, right panel) and synoviolin expression measured by real-time RT-PCR. The results are expressed as the ratio of synoviolin/b-actin mRNA
amplification, n=3, mean 6 SEM of duplicate experiments from 3 different RA donors. * P,0.05 compared to no treatment control. RA FLS were
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PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13416for IL-17RC in protection against apoptosis has been reported in a
prostate cancer line whereby IL-17RC inhibits caspase 2, 8 and
subsequently caspase 3 [17]. In contrast an anti-apoptotic effect of
IL-17RA has not previously been described. Similarly both IL-
17R components were involved in IL-17 induced p65 NFkB and
c-fos AP-1 activation in RA FLS. This is consistent with human
and murine data demonstrating the requirement for both IL-
17RA and IL-17RC subcomponents in the biological effects of IL-
17 [23,33]. In contrast to the clear anti-apoptotic effects of IL-17,
IL-17 (1-100 ng/ml) over 6 h, 24 h, 48 h or 7 days did not
significantly stimulate RA FLS proliferation (data not shown).
We observed that IL-17R mediated ERK and JNK activation
were required in RA FLS synoviolin expression. Cytokine induced
ERK MAPK and Ets 1 transcription factor have been reported to
control synoviolin expression in mouse cells [5]. In contrast to IL-
17-dependent synoviolin in human RA FLS, in mouse cells Gao
et al [5] demonstrated that JNK activation is dispensable for IL-
1b-dependent synoviolin expression. The differences observed
may be cytokine dependent and/or associated with mouse/human
cell differences. NFkB binding sites are not present in the
synoviolin promoter. These data suggest that IL-17R-induced
synoviolin expression via ERK and JNK MAPK activation
contributes to protection against apoptosis in RA FLS. MAPK
and AP-1 activation have an established role in cell survival.
The underlying mechanism for IL-17-mediated protection
against RA FLS apoptosis may be associated at least in part to
IL-17 induced synoviolin expression. Synoviolin RNA interference
enhances ER stress induced apoptosis in RA FLS[34], and in this
study synoviolin siRNA augments SNP-induced RA FLS apopto-
sis. Herein, IL-17 treatment subsequently reduced synoviolin
siRNA-induced RA FLS apoptosis, rescued RA FLS from SNP-
induced apoptosis and dose dependently induced synoviolin
expression. Furthermore, either IL-17 or synoviolin inhibition
enhanced SNP-induced apoptosis. Complete abrogation of
synoviolin knockdown-induced apoptosis at high doses of SNP
required the combination of both IL-17 and TNF consistent with
the additive effects of this cytokine combination on synoviolin
induction. IL-17 had more potent effects than TNF on synoviolin
induction and protection against RA FLS apoptosis. Thus, in
addition to additive effects of IL-17 and TNF on inflammation and
bone destruction this cytokine combination enhanced anti-
apoptotic effects of IL-17. In the mixed cytokine milieu of an
inflammed arthritic joint, other proinflammatory cytokines may
enhance the protective effects of IL-17 against FLS apoptosis
implicated in synovial hyperplasia contributing to pannus
persistence and chronicity. It is possible that IL-17 may also exert
its anti-apoptotic effects in a synoviolin independent manner such
as through induction of NFkB, MAPK and AP-1. Both
endogenous and cytokine induced synoviolin expression in RA
FLS promote RA FLS survival.
It is unclear how IL-17-induced or endogenous synoviolin
expression may be anti-apoptotic in RA FLS. Recent data
suggests that the tumour suppressor gene, p53 may be regulated
by synoviolin [6]. Synoviolin binds to, ubiquitinates and
degrades cytoplasmic p53. Furthermore, IL-17 rescued RA
FLS from SNP-induced apoptosis. SNP is a nitric oxide (NO)
d o n o r ,a n de l e v a t e dN Ol e v e l sp l a yak e yr o l ei na p o p t o s i so f
cells involved in the inflammatory response. NO mediates
apoptosis by both p53-mediated apoptosis [35] and ER-stress
induced apoptosis [36,37]. Although it is tempting to speculate
that IL-17 may indirectly modulate p53 expression through
synoviolin expression we were unable to confirm this hypothesis
a tl e a s ta tt i m e p o i n t su pt o2 4ho fI L - 1 7t r e a t m e n t( d a t an o t
shown). IL-17 did not suppress p53 protein expression in
timepoints up to 24 h despite rescue of RA FLS from SNP-
induced apoptosis by IL-17, associated with increased synoviolin
expression. IL-17 increased p53 expression prior to synoviolin
expression at 4 h and 6 h respectively following IL-17A
treatment which was sustained out to 24 h (data not shown).
However, the time course needs to be extended to examine
whether p53 degradation occurs following synoviolin induction
beyond 24 h. Moreover, synoviolin sequesters p53 in the ER. It
would be interesting to examine p53 sequestration following IL-
17-induced synoviolin upregulation, and the ubiquitination
status of p53 at later timepoints. Although, IL-17 was capable
of inducing both synoviolin and p53 the net effect was anti-
apoptotic. Other proinflammatory cytokines such as MIF have
clear protective effects against SNP-induced apoptosis in RA
FLS through marked downregulation of p53 expression [32].
Interestingly we identified synoviolin and IL-17 coexpressing
cells in synovial germinal centre and follicle-like structures in WT
mice with SCW-induced arthritis. Th17 cells have been recently
described to play a key role in germinal centre formation [38]. We
previously described synoviolin expression in peripheral blood
CD3 + T cells from RA patients [3]. In addition, such synoviolin
expressing Th17 cells were found in close contact with synoviolin
expressing CD19 + B cells in follicle-like structures of these mice.
Subsequent to this finding we cell sorted human CD19 + B cells
from the peripheral blood of RA patients and found that
synoviolin was also highly expressed in the blood (data not
shown). Germinal centre-like structures including synoviolin
expression were completely absent in IL-17R deficient mice. IL-
17R signaling has been demonstrated to be critical for the
formation of such structures in an autoimmune model of arthritis
as in autoimmune BXD2 mice [38]. In this study the coexistence
of Th17 cells and B cells expressing synoviolin suggests that it may
be a prosurvival factor for such cells in addition to RA FLS. B cells
have a clear pathogenic role in RA as demonstrated by the efficacy
of B cell depletion with anti-CD20 mAbs in the clinic [39]. It
remains to be determined if IL-17 antagonists may directly reduce
circulating and synovial B-cells in a similar way to current anti-
TNF biologics or anti-B cell therapies [39,40].
We describe a novel role for IL-17 in RA FLS survival via
downregulation of FLS apoptosis. IL-17RA and IL-17RC
mediated signaling and synoviolin expression may contribute to
dysregulated RA FLS growth. Anti-apoptotic effects of IL-17-
induced synoviolin are enhanced by TNF. Persistence of synovial
Th17 synoviolin-expressing cells in close contact with B cells in
germinal centre structures may further contribute to chronicity.
These observations have important implications in the interaction
between T cells and other stromal cells in the progression from
initial synovial inflammation to hyperplastic pannus formation.
Future IL-17 antagonists may limit both synovial inflammation
and hyperplasia. Targeting IL-17 may improve efforts to control
the chronicity of the disease, possibly in addition or following the
control of inflammation with current cytokine inhibitors.
pretreated with IL-17 100 ng/ml for 2 h then cotreated with SNP 0.1-1 mM for 24 h and apoptosis measured by SS DNA apoptosis kit (C). The results
are presented as the fold induction in apoptosis relative to control samples, n=3, mean 6 SEM of duplicate experiments from 3 different RA donors.
* P,0.05 compared to no treatment control. RA FLS were treated as above and annexin V analysed. Representative serial fluorescent microscopic
pictures of Annexin V positive cells (green), double labelled with Propidium iodide (PI, red) at magnification x 200 (D).
doi:10.1371/journal.pone.0013416.g002
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PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13416Figure 3. Effect of IL-17RA or IL-17RC knockdown on apoptosis, synoviolin expression in RA FLS. To confirm specificity of siRNA
knockdown of individual IL-17 receptors, RA FLS were nucleofected (amaxa) for 24 h with 0.5 mg IL-17RA (siRA), 0.05 mg IL-17RC (siRC) or
siCONTROL siRNA (sictl) serum starved overnight then treated 50 ng/ml IL-17A for 8 h. IL-17RA or IL-17RC protein expression was measured by
Western Blot. Membranes were stripped and reprobed for actin as a loading control (A). IL-17RA or IL-17RC mRNA expression was measured by real-
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PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13416time RT-PCR, normalised to GAPDH and expressed as percentage inhibition compared to sictl siRNA (B). * P,0.05, compared to sictl nucleofected RA
FLS. RA FLS were nucleofected as above, serum starved overnight then pretreated with 50 ng/ml IL-17A for 2 h then cotreated with SNP 0.1 mM
overnight and apoptosis measured by SS DNA apoptosis assays expressed as fold induction of apoptosis (C), n=3 from 3 separate RA donors, mean
6 SEM of duplicate experiments. * P,0.05, compared to sictl nucleofected RA FLS. RA FLS were nucleofected as above serum starved overnight then
treated with 50 ng/ml IL-17A and (D) synoviolin levels analysed by real-time RT-PCR. Synoviolin mRNA level was normalized to GAPDH and expressed
as fold increase over sictl siRNA treated samples, n=5, mean 6 SEM of duplicate experiments. * P,0.05, compared to sictl nucleofected RA FLS.
{ P,0.05 compared to IL-17 sictl treated samples. RA FLS were pretreated with 2 mg/ml of anti-IL-17RA or anti-IL-17RC Abs or isotype control goat
Abs for 2 h then cotreated with IL-17 50 ng/ml for 24 h and synoviolin expression measured by real-time RT-PCR (E) , n=3, mean 6 SEM. * P,0.05,
compared to untreated control. { P,0.05 compared to IL-17 treated samples.
doi:10.1371/journal.pone.0013416.g003
Figure 4. Effect of synoviolin knockdown on apoptosis in RA FLS. RA FLS were nucleofected (amaxa) for 24 h with 0.5 mg of 4 synoviolin
siRNA duplexes (S-01 to S-04), synoviolin smartpool siRNA duplex or siCONTROL siRNA (sictl) and synoviolin expression analysed by real-time RT-PCR
(A, left panel) or Western Blot (A, right panel). Synoviolin mRNA was normalized to GAPDH and results expressed as the percentage fold
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Ethics statement
The use of patient biological samples and this study was reviewed
and approved by the local institutional review committee of the
hospital of Lyon, and patients gave informed written consent.
Isolation and culture of RA FLS
RA FLS were obtained from synovial tissue obtained from RA
patients undergoing joint surgery who fulfilled the American
College of Rheumatology criteria for RA [41]. Osteoarthritis (OA)
FLS or dermal fibroblasts were obtained from the joint or the skin
of patients with OA undergoing joint surgery; these cells were used
reduction compared to sictl treated samples, n=5, mean 6 SEM of duplicate experiments. * P,0.05, compared to sictl nucleofected RA FLS. (B), RA
FLS were nucleofected as above then treated with SNP 0.1–1 mM overnight and apoptosis measured by the SS DNA apoptosis assay. Results are
expressed as fold induction in apoptosis, n=3 from 3 separate RA donors, mean 6 SEM of duplicate experiments. * P,0.05, compared to sictl
nucleofected RA FLS. (C), RA FLS were nucleofected as above, serum starved overnight then pretreated with 100 ng/ml IL-17A for 2 h then cotreated
with SNP 0.1–1 mM overnight and apoptosis measured by SS DNA apoptosis assays expressed as fold induction of apoptosis, n=3 from 3 separate RA
donors, mean 6 SEM of duplicate experiments. * P,0.05, compared to sictl nucleofected RA FLS. { P,0.05 compared to SNP treatment in S-08
nucleofected RA FLS.
doi:10.1371/journal.pone.0013416.g004
Figure 5. Effect of IL-17 and TNF on RA FLS synoviolin expression and apoptosis. RA FLS were stimulated with IL-17A (50 or 100 ng/ml)
and/or TNF (1 or 10 ng/ml) for 24 h and synoviolin mRNA expression measured by real-time RT-PCR (A). The results based on a ratio of synoviolin/b-
actin mRNA amplification are presented as the fold induction in synoviolin mRNA expression relative to control samples, n=3, mean 6 SEM. * P,0.05
compared to no treatment control. { P,0.05 compared to TNF treated samples. RA FLS were pretreated with IL-17 100 ng/ml and TNF 10 ng/ml for
2 h then cotreated with SNP 0.5 mM( B, left panel) or 0.1 mM( B, right panel) for 24 h and apoptosis measured by SS DNA apoptosis kit. The results
are presented as the fold induction in apoptosis relative to control samples, n=3, mean 6 SEM of duplicate experiments from 3 different RA donors.
* P,0.05 compared to SNP treatment in S-08 nucleofected RA FLS.
doi:10.1371/journal.pone.0013416.g005
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were isolated by enzyme digestion and cultured in DMEM/10%
FCS as described [3]. Cells beyond the third passage were .99%
CD45 negative, and used between passages 4 and 9. Cultured RA
FLS were treated with IL-17A or IL-17F 50 ng/ml (R&D
Systems, Minneapolis, MN), IL-1b 0.1 ng/ml (Sigma-Aldrich),
LPS 100 ng/ml (Sigma-Aldrich), TNFa 1 ng/ml (Biosource,
Carmarillo, CA). IL-17RA or IL-17RC were antagonized with
anti-IL-17RA mAb or anti-IL-17RC polyclonal goat Ab (R&D
Systems). ERK, p38 and JNK MAPK were antagonized with
PD98059 (50mM, chemicon)[42], SB203580 (5mM, chemi-
con)[43], or SP600125 (50mM, chemicon)[44].
RNA interference
Gene-specific small interfering RNA (siRNA) corresponding to
a 19-nucleotide sequence targeting 1623–1641 of human IL-17RA
(IL-17RA siRNA, NM_014339), 985–1003 of human IL-17RC
(IL-17RC siRNA, NM_153460) or human synoviolin (Synoviolin
siRNA, NM_032431) were purchased from Dharmacon (Lafay-
ette, CO, USA). A non-targeting siRNA (siCONTROL) was used as
a control for non-sequence-specific effects. RA FLS (1610
5) were
transfected with 0.5 mg IL-17RA, IL-17RC, synoviolin siRNA or
siCONTROL siRNA duplexes using a human dermal fibroblast
nucleofector kit, protocol U-23 (Amaxa GmbH, Cologne,
Germany)[23].
Apoptosis
RA FLS were treated with sodium nitroprusside (sigma) 0.01–
0.5 mM for 24 h at 37uC. Apoptosis was analysed by annexin V
expression (BD biosciences) by flow cytometry (Fluorescence
activator cell sorter scan, Becton-Dickinson, Mountain View,
CA) or fluorescence microscopy using an Axiovert 135 microscope
(Zeiss) equipped with an AxioCam camera. Dead cells were
excluded by PI staining. Apoptosis was also measured by a single
stranded DNA (SS DNA) apoptosis ELISA kit (chemicon).
Western Blot analysis
Synoviolin expression was examined by Western blot using
antibodies against synoviolin (Abgent) [3] or b-actin (Santa Cruz,
Cell Signaling Laboratories) as described previously [45].
Membranes were stripped and serially reprobed with antibodies
against synoviolin and b-actin used as a loading control.
Real-time RT-PCR Analysis
1 mg of RNA extracted using TRIzol reagent (Gibco BRL) was
reverse transcribed using Thermoscript RT-PCR system (Invitro-
gen, California, USA) and PCR amplification performed on a
LightCycler (Roche) using Fast-StartTM DNA Master SYBR
Green I real-time PCR kit (Roche Molecular Biochemicals) [3].
Primer-specific nucleotide sequences for c-fos (Search-LC GmbH,
Heidelberg, Germany), c-jun (Search-LC GmbH, Heidelberg,
Figure 6. Synoviolin expression during chronic streptococcal cell wall-induced arthritis in wild-type (WT) mice. A representative image
of synoviolin-positive staining diffusely (A) or in follicle-like structures of synovium (B and C, magnification X 200). Double immunostaining showing
colocalisation of synoviolin (brown) and CD20 (blue) staining (D, magnification X 600) or IL-17 (blue) staining (E, magnification X 600) or isotype
control (F, magnification X 600) in follicle-like structures of arthritic knee joints from WT mice. Synoviolin staining in synoviocytes infiltrating cartilage
at the pannus-cartilage junction (G, magnification X 400).
doi:10.1371/journal.pone.0013416.g006
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PLoS ONE | www.plosone.org 10 October 2010 | Volume 5 | Issue 10 | e13416Figure 7. Severity of chronic streptococcal cell wall-induced arthritis in wild-type (WT) or IL-17R
2/2 mice (A). A representative image of
haematoxylin and eosin-stained synovial knee joint sections in WT or IL-17R
2/2 mice at day 42 after 5 repeated injections of streptococcal cell wall
(SCW) fragments (magnification 640). Arthritis severity and inflammatory infiltrate were scored histologically in injected joints of WT or IL-17R
2/2
mice. Arthritis severity was scored on a scale of 0–2 and synovial infiltrate on a scale of 0–3. Results are expressed as mean 6 SEM of 2 separate
experiments, n=10 mice per group per experiment, * P,0.05 compared to WT mice. Synoviolin expression is reduced in IL-17R
2/2 mice with
chronic SCW-induced arthritis (B). Synoviolin expression in sections of arthritic knee joints from, a wild-type (WT) or IL-17R
2/2 mouse after 5
repeated injections of SCW fragments (magnification x 40, day 42, n=10 mice in WT or IL-17R
2/2 groups from 2 separate experiments). Synoviolin
expression was quantified in 10 high power fields, averaged and expressed as the number of synoviolin positive cells/mm
2,*P,0.05 compared to WT
mice. Synovial apoptosis in WT or IL-17R
2/2 mice with chronic streptococcal cell wall-induced arthritis (C). A representative image of
increased TUNEL staining in IL-17R
2/2 synovium (magnification 6200.). The number of TUNEL-positive cells was quantified in 10 high power fields,
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(accession number: X00351, 59-TGTCCCTGTATGCCTCTGGT-
39 and 59-GATGTCACGCACGATTTCC-39)o rG A P D H( S e a r c h -
LC GmbH, Heidelberg, Germany) were used and genes measured by
quantitative real-time RT-PCR (RT-PCR).
Chronic SCW-induced arthritis model
The mice and the arthritis model have been previously
described in detail [30]. All in vivo mouse studies complied with
national legislation and were approved by local authorities of the
Care of Use of Animals of the University of Nijmegen, the
Netherlands. Animals were housed under conventional conditions,
water and standard laboratory chow were provided ad libitum.
Specific pathogen–free C57BL/6 mice (males and females, ages 8–
10 weeks; National Cancer Institute, Frederick, MD) were used as
WT controls for the IL-17R
–/– mice. The IL-17R
–/– mice were
obtained from Dr. J. J. Peschon (Amgen, Seattle, WA). Arthritis
was induced in WT and IL-17R
–/– mice by the intraarticular
injection of 25 mg of streptococcal cell wall (SCW) fragments in
6 ml of phosphate buffered saline into the knee joints. Chronic
arthritis was induced by 5 repeated injections of 25 mg of SCW
administered intraarticularly at 1-week intervals. On day 42, mice
were killed by cervical dislocation and knee joints were isolated for
histological analysis. The arthritis severity and inflammatory
infiltrates were scored as previously described .
Detection of synoviolin expressing cells
Mouse joints were fixed in 10% formalin, decalcified in formic
acid and embedded in paraffin. Briefly for single staining,
synoviolin expression was measured by immunohistochemistry
using 12.5 mg/ml of a polyclonal rabbit antibody against
synoviolin (Abgent). In negative control sections, irrelevant
antibody (goat serum) was applied., and counterstained with
haematoxylin [46,47]. Cells positive for synoviolin were quantified
by counting positive cells in ten consecutive high power fields (x
200). The number of positive cells per high power field was
averaged and the results expressed as the number of synoviolin
positive cells per mm
2 using Histolab
TM microvision version 5.9.2
[48]. For double staining, sections were incubated with a
polyclonal rabbit antibody against synoviolin (Abgent) followed
by biotinylated anti-rabbit immunoglobulins, and streptavidin-
peroxidase (DAKO, Glostrup, Denmark). Peroxidase was devel-
oped by 3,39 diaminobenzidine chromogen solution (DAB)
(DAKO, Glostrup, Denmark). Goat polyclonal anti-mouse
CD20 (4 mg/ml, Santa Cruz Biotechnology, Europe) and goat
polyclonal anti-mouse IL-17 antibodies (10 mg/ml, R&D Systems
Europe, London, UK) were followed by biotinylated anti-goat
immunoglobulins (DAKO, Glostrup, Denmark) and streptavidin-
alkaline phosphatase (DAKO, Glostrup, Denmark). Alkaline
phosphatase was revealed using Vector Blue as chromogen (blue
color; Vector Labs, Burlingame, CA, USA). In negative control
sections, irrelevant antibody (rabbit or goat serum) was applied.
In situ apoptosis and proliferation in chronic SCW
arthritis
TUNEL staining was performed using an in situ death detection
kit (Roche, Mannheim, Germany) according to the manufacturer’s
instructions. Synovial proliferation was determined by immuno-
staining using a specific Mab to the proliferation marker PCNA
(Santa Cruz Biotechnology). Tunnel or PCNA-positive cells in
murine synovial tissue samples were counted in a blinded manner
in ten high-power fields per section, an average score was obtained
and results expressed as the number of Tunnel or PCNA-positive
cells mm
2 using Histolab
TM microvision version 5.9.2.
Statistical analysis
Results are expressed as the mean 6 SEM. Analysis was
performed using the Mann Whitney U-test and P values ,0.05
considered statistically significant. All data are the result of at least
3 separate experiments from 3 individual human RA donors.
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